Located in the San Francisco Bay Area, Medaysis develops and delivers primary antibodies, polymer detection kits for immunohistochemistry (IHC), immunofluorescence (IF) single or double staining, and in situ hybridization (ISH) for cancer, infectious diseases, neuroscience and other life science research. Medaysis provides a comprehensive portfolio of products including more than 600 primary antib
odies, a broad range of detection reagents and a variety of tissues. We are passionate and strive to continuously introduce novel antibodies and new solutions to enable pathologists, histologists and researchers to design experiments, improve test accuracy and achieve reliable results. We recently introduced ultra-sensitive CloDiA™ PCR-based mutation detection systems designed with novel and proprietary primers that are able to detect 1% or less common somatic mutations in the genes. Our mission is to provide advanced technologies and quality solutions that will empower the innovation and improve the practice of anatomic and molecular pathology professionals, ultimately to develop accurate diagnostic assays and personalized healthcare to benefit the patients and well-being of individuals around the world.
